Literature DB >> 25445065

Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders.

Stephanie A Ballendine1, Quentin Greba1, Wojciech Dawicki2, Xiaobei Zhang2, John R Gordon2, John G Howland3.   

Abstract

Research suggests that maternal immune activation (MIA) during pregnancy increases the risk of neurodevelopmental disorders including schizophrenia and autism in the offspring. Current theories suggest that inflammatory mediators including cytokines and chemokines may underlie the increased risk of these disorders in humans. For example, elevated maternal interleukin-8 (IL-8) during pregnancy is associated with increased risk of schizophrenia in the offspring. Given this association, the present experiments examined ELR-CXC chemokines CXCL1 and CXCL2, rodent homologues of human IL-8, and activation of their receptors (CXCR1 and CXCR2) in an established rodent model of MIA. Pregnant Long Evans rats were treated with the viral mimetic polyinosinic-polycytidylic acid (polyI:C; 4 mg/kg, i.v.) on gestational day 15. Protein analysis using multiplex assays and ELISA showed that polyI:C significantly increased maternal serum concentrations of interleukin-1β, tumor necrosis factor, and CXCL1 3h after administration. Subsequent experiments tested the role of elevated maternal CXCL1 on behavior of the offspring by administering a CXCR1/CXCR2 antagonist (G31P; 500 μg/kg, i.p.; 1h before, 48 and 96 h after polyI:C treatment). The male offspring of dams treated with polyI:C demonstrated subtle impairments in prepulse inhibition (PPI), impaired associative and crossmodal recognition memory, and altered behavioral flexibility in an operant test battery. While G31P did not completely reverse the behavioral impairments caused by polyI:C, it enhanced PPI during adolescence and strategy set-shifting and reversal learning during young adulthood. These results suggest that while polyI:C treatment significantly increases maternal CXCL1, elevations of this chemokine are not solely responsible for the effects of polyI:C on the behavior of the offspring.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crossmodal memory; Interleukin-8; Polyi:C; Schizophrenia; Set-shifting

Mesh:

Substances:

Year:  2014        PMID: 25445065      PMCID: PMC4464825          DOI: 10.1016/j.pnpbp.2014.11.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  75 in total

Review 1.  Cytokines and CNS development.

Authors:  Benjamin E Deverman; Paul H Patterson
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

2.  The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.

Authors:  John R Gordon; Fang Li; Xiaobei Zhang; Wenjun Wang; Xixing Zhao; Aarti Nayyar
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

3.  Maternal immune activation impairs reversal learning and increases serum tumor necrosis factor-α in offspring.

Authors:  Xiao Han; Nanxin Li; Qingxuan Meng; Feng Shao; Weiwen Wang
Journal:  Neuropsychobiology       Date:  2011-05-14       Impact factor: 2.328

4.  Placental TNF-α signaling in illness-induced complications of pregnancy.

Authors:  Pamela A Carpentier; Andra L Dingman; Theo D Palmer
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 5.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

6.  A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex.

Authors:  Jennifer J Donegan; Milena Girotti; Marc S Weinberg; David A Morilak
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

7.  Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development.

Authors:  Paula A Garay; Elaine Y Hsiao; Paul H Patterson; A K McAllister
Journal:  Brain Behav Immun       Date:  2012-07-25       Impact factor: 7.217

Review 8.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

9.  Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring.

Authors:  Alan S Brown; Jonathan Hooton; Catherine A Schaefer; Haiying Zhang; Eva Petkova; Vicki Babulas; Megan Perrin; Jack M Gorman; Ezra S Susser
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

10.  CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection.

Authors:  Jing Wei; Jing Peng; Bing Wang; Hong Qu; Shiyi Wang; Aziz Faisal; Jia-Wei Cheng; John R Gordon; Fang Li
Journal:  Biomed Res Int       Date:  2013-03-18       Impact factor: 3.411

View more
  17 in total

1.  Dissociable effects of the d- and l- enantiomers of govadine on the disruption of prepulse inhibition by MK-801 and apomorphine in male Long-Evans rats.

Authors:  Brittney R Lins; Wendie N Marks; Anthony G Phillips; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2017-02-08       Impact factor: 4.530

2.  Variability in PolyIC induced immune response: Implications for preclinical maternal immune activation models.

Authors:  Milo Careaga; Sandra L Taylor; Carolyn Chang; Alex Chiang; Katherine M Ku; Robert F Berman; Judy A Van de Water; Melissa D Bauman
Journal:  J Neuroimmunol       Date:  2018-06-28       Impact factor: 3.478

Review 3.  Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates.

Authors:  Milo Careaga; Takeshi Murai; Melissa D Bauman
Journal:  Biol Psychiatry       Date:  2016-10-25       Impact factor: 13.382

4.  Aberrant Phase Precession of Lateral Septal Cells in a Maternal Immune Activation Model of Schizophrenia Risk May Disrupt the Integration of Location with Reward.

Authors:  Lucinda J Speers; Robert Schmidt; David K Bilkey
Journal:  J Neurosci       Date:  2022-04-08       Impact factor: 6.709

Review 5.  Brain changes in a maternal immune activation model of neurodevelopmental brain disorders.

Authors:  Lara Bergdolt; Anna Dunaevsky
Journal:  Prog Neurobiol       Date:  2018-12-24       Impact factor: 11.685

Review 6.  Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model.

Authors:  Amanda C Kentner; Staci D Bilbo; Alan S Brown; Elaine Y Hsiao; A Kimberley McAllister; Urs Meyer; Brad D Pearce; Mikhail V Pletnikov; Robert H Yolken; Melissa D Bauman
Journal:  Neuropsychopharmacology       Date:  2018-08-21       Impact factor: 7.853

7.  In utero immune programming of autism spectrum disorder (ASD).

Authors:  Sukanta Jash; Surendra Sharma
Journal:  Hum Immunol       Date:  2021-02-19       Impact factor: 2.850

8.  A Window on the Study of Aversive Instrumental Learning: Strains, Performance, Neuroendocrine, and Immunologic Systems.

Authors:  Caroline C de Oliveira; Flávia V Gouveia; Marina C de Castro; Mayra A Kuroki; Lennon C T Dos Santos; Erich T Fonoff; Manoel J Teixeira; José P Otoch; Raquel C R Martinez
Journal:  Front Behav Neurosci       Date:  2016-08-24       Impact factor: 3.558

9.  Developmental disruption of perineuronal nets in the medial prefrontal cortex after maternal immune activation.

Authors:  John W Paylor; Brittney R Lins; Quentin Greba; Nicholas Moen; Reiner Silveira de Moraes; John G Howland; Ian R Winship
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

10.  Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic.

Authors:  Brittney Lins
Journal:  Brain Behav Immun Health       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.